Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Treatment of hepatitis C virus (HCV) has improved with new direct-acting antiviral therapies, resulting in improved sustained virological response (SVR) rates, as compared with the treatment with pegylated interferon and ribavirin (RBV).1 ,2 Despite these improvements, direct-acting agents have been linked to resistance when used without interferon therapy. The guidelines recommend their use in combination with peginterferon α and RBV as optimal therapy in HCV genotype 1.1 ,2 However, this addition adds complexity to the medication regimen, potentially causing adverse effects and potential for drug interactions.2 The aim of this phase 2 study …
Competing interests None.